SCHEMBL16626637

SCHEMBL16626637

CNCc1cn(S(=O)(=O)c2cccnc2)c2cc(-c3ccnc(F)c3)ccc12

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR1D1 P20393 2/20 0.38
HTR6 P50406 6/20 0.38
IDE P14735 1/20 0.37
RORC P51449 3/20 0.35
MAPT P10636 2/20 0.35
LRRK2 Q5S007 1/20 0.34
SSTR5 P35346 1/20 0.34
KCNH2 Q12809 1/20 0.34
PIK3C3 Q8NEB9 1/20 0.34
PDPK1 O15530 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
EPHX2 P34913 1/20 0.33
PRMT6 Q96LA8 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL16619510 0.99 NR1D1 (0.38) NR1D1HTR6IDERORCMAPT
SCHEMBL16626771 0.92 HTR6 (0.39) NR1D1HTR6IDERORCMAPT
Hydrochloric Acid SCHEMBL16618564 0.91 NR1D1 (0.38) NR1D1HTR6IDERORCSSTR5
SCHEMBL16619000 0.88 HTR6 (0.46) NR1D1HTR6IDEPDPK1EPHX2
SCHEMBL16619172 0.88 HTR6 (0.46) NR1D1HTR6IDEPDPK1EPHX2
SCHEMBL17971570 0.87 HTR6 (0.40) NR1D1HTR6IDEPDPK1PDE4A
SCHEMBL17971569 0.86 GRIN2B (0.39) NR1D1HTR6IDEPDPK1PDE4A
Hydrochloric Acid SCHEMBL16618679 0.86 GRIN2B (0.39) NR1D1HTR6IDERORCPDPK1
SCHEMBL16619001 0.86 HTR6 (0.42) NR1D1HTR6IDE
Hydrochloric Acid SCHEMBL16619511 0.86 HTR6 (0.40) NR1D1HTR6IDERORCPDE4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP claimed
EP-3052484-B1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAE WOONG PHARMA (KR) 2018-03-21 EP disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-9676714-B2 Sulfonylindole derivatives and method for preparing the same DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2017-06-13 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2016-08-04 US disclosed
WO-2015050412-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME DAEWOONG PHARMACEUTICAL CO., LTD. (KR) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160221946-A1 SULFONYLINDOLE DERIVATIVES AND METHOD FOR PREPARING THE SAME GIPR, PGC, SI NR1D1 2493/4885HTR6 166/4885IDE 2586/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.